about
Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysisNon-invasive assessment of liver fibrosis in chronic hepatitis B.The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients.The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent.Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusionPerformance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection.HBV and HCV therapy.Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infectionProphylaxis and treatment of hepatitis B in immunocompromised patients.Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.Antiviral drugs for HBV liver disease.Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon.Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis?Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management.Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense.PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.Results of treatment of chronic hepatitis B with pegylated interferon.HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy.Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.Optimal management of hepatitis B virus infection - EASL Special Conference.Decompensated Cirrhosis and Sickle Cell Disease: Case Reports and Review of the Literature.The prognosis and management of inactive HBV carriers.Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders.Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients.Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection.Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B.The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B.Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs).Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal.IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients.PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B.
P50
Q26865747-AE0136D3-E25D-44AF-9C88-787EF6C7609AQ27016075-40082446-3ABC-4C33-A8B2-056EAE38EFA1Q30427489-5B50B84A-8FB8-4418-8584-8A4594E32D2AQ30586377-0225EEEF-F063-40E9-BD99-BBB264977ED9Q33755525-7D1D909D-D446-4656-86D2-5458C5BA4BBDQ34375921-122EB38F-9F32-42BA-9A94-A50E5AD6EF79Q34981143-9B584E25-EDB8-4FAE-9EF8-975DEBDD20C1Q35259824-94E017A8-226E-482C-B56C-43EBC5DB0FC7Q36052963-88F29E9B-CE0C-47CA-9A61-01A0E6041066Q36267204-62027D8D-2A75-494E-AD29-505432BEC906Q36345904-846400B3-2B3F-4E53-A081-7E07B1BE7CA2Q36768889-19C1EE50-7FB0-4DB2-BF17-CA7162DCDE56Q37756309-4844039C-A44F-4BF7-9A9B-7E7568BD099AQ37825909-693332DB-6B75-4974-8502-8CE4623BF17AQ37825961-3F2CA13F-AA17-4E27-8295-304200BBE317Q37833228-0C95262E-BB02-4A72-B77C-0D64969E159CQ37857522-1A63509D-6943-4E9C-BC89-02F9BA85DA8AQ37970447-B6A7872A-9CA7-4FED-9FFE-ED0FAFB9BC76Q38023098-F4118EBE-C3E5-4355-B4BA-D94733646D9AQ38102776-7B649C4E-D906-45DC-AA91-D1C38FD593D2Q38125739-2CCDA386-6B98-43B8-B289-6727A6E72623Q38174260-1D2652C6-7CC8-4A1F-A293-4E4602560A01Q38218566-A3B2A64F-C69A-49CD-B630-8A0C2365B521Q38295855-15E15FE3-75EE-4291-BBB8-0C991EB526ADQ38321507-B64ED903-7D7B-453F-B6A8-B5BDE85F0775Q38543469-DD2ADFD1-5416-46C9-BDEE-68CCD8176216Q38684237-52A59BBA-2567-4995-B996-C8B80CB991EAQ38685595-B5597697-4411-484F-A41D-6A784DF1C416Q38810735-31ADEE0A-AF50-46E6-B773-64B1A1621E6EQ38839020-5C927704-41A4-42EA-97A3-43EE95AD6EFAQ38928531-8917D707-F722-47C3-BC0C-9E8DE0335B35Q38964920-547BBDD2-BF31-4347-A41E-8555E707E8FBQ38992814-4014A8A8-7CB4-44C1-A641-7926EDE537ECQ39043903-B0075CDA-125F-4537-8ABF-B123C45D2FC4Q39067311-CDCA94DF-1D2D-4F49-972E-C9B380ADC3D2Q39560382-7953C2BC-F92A-490B-A3F0-ED14E34B5AEFQ40113190-BEB0E431-450A-4FA1-963E-B4AF9DD45EF1Q40201303-6F6B9BB1-311C-4F9B-B5B3-974B3D1F8E42Q40253276-28B42F28-3B57-4CAE-824F-76C2FFBA7963Q40343692-488C7744-85EF-4465-BA0B-136D4D29B857
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pietro Lampertico
@ast
Pietro Lampertico
@en
Pietro Lampertico
@es
Pietro Lampertico
@nl
Pietro Lampertico
@sl
type
label
Pietro Lampertico
@ast
Pietro Lampertico
@en
Pietro Lampertico
@es
Pietro Lampertico
@nl
Pietro Lampertico
@sl
prefLabel
Pietro Lampertico
@ast
Pietro Lampertico
@en
Pietro Lampertico
@es
Pietro Lampertico
@nl
Pietro Lampertico
@sl
P106
P1153
7006770607
P21
P31
P496
0000-0002-1026-7476